A retrospective study in patients who were diagnosed with pathologically confirmed stage I to stage IV NSCLC and initiated nivolumab or pembrolizumab in 2016.
Latest Information Update: 24 Jan 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Jan 2020 New trial record
- 14 Jan 2020 Results published in the Cancer